Home/cascade-timeline/Pfizer Reports $22 Billion Profit on COVID-19 Vaccine, One of Most Profitable Drugs in History

Pfizer Reports $22 Billion Profit on COVID-19 Vaccine, One of Most Profitable Drugs in Historytimeline_event

covid-19regulatory-capturehealthcarepharmaceutical-price-gougingcorporate-profiteering
2021-11-02 · 8 min read · Edit on Pyrite

type: timeline_event

In November 2021, Pfizer reported annual profits of $21.98 billion on revenues of $81.29 billion for 2021, with COVID-19 vaccine sales of $36.7 billion accounting for 45% of total company revenue. The COVID-19 vaccine became one of the most financially successful pharmaceutical products in history, generating massive profits while relying on publicly-funded research, government advance purchase commitments, and liability protections—demonstrating how pharmaceutical companies privatize publicly-funded innovation while extracting maximum profits during public health emergencies.

Historic Profits from Public Health Crisis

Pfizer's 2021 financial results represented extraordinary profit extraction from the COVID-19 pandemic:

Revenue Breakdown:

  • Total 2021 revenue: $81.29 billion (92% operational growth from 2020)
  • COVID-19 vaccine revenue: $36.7 billion (45% of total)
  • Total 2021 profit: $21.98 billion (approximately 100% increase from 2020)
  • Vaccine profit margin: High 20% range

    • 2022 Projections:

  • Expected COVID vaccine revenue: $32 billion
  • Expected Paxlovid (treatment) revenue: $22 billion
  • Combined COVID product revenue: $54 billion

    • Two-Year Total: Analysis showed Pfizer generated approximately $35 billion in net profits specifically from COVID-19 products during 2021-2022 combined.

    These figures made Pfizer's COVID vaccine one of the most profitable pharmaceutical products ever developed, surpassing blockbuster drugs that took decades to generate comparable revenues.

    Publicly-Funded Research, Privatized Profits

    Pfizer's massive COVID vaccine profits relied heavily on public sector investment and support:

    Government Research Funding:

  • mRNA technology underlying the vaccine was developed through decades of publicly-funded research at universities and NIH
  • BioNTech (Pfizer's partner) received €375 million ($445 million) from the German government for vaccine development
  • U.S. Operation Warp Speed provided billions in advance purchase commitments, eliminating commercial risk

    • Liability Protection:

  • PREP Act provided complete liability protection for vaccine manufacturers
  • Companies face no legal liability for adverse reactions, injuries, or deaths
  • Taxpayers bear all costs through the Vaccine Injury Compensation Program

    • Regulatory Fast-Track:

  • FDA provided expedited Emergency Use Authorization
  • Ongoing regulatory support and priority review
  • Government resources dedicated to facilitating rapid approval

    • Despite this massive public investment and support, Pfizer retained full patent rights and pricing power, allowing the company to extract maximum profits from publicly-funded innovation.

    Pricing Strategy: Maximum Extraction

    Pfizer's pricing demonstrated aggressive profit maximization:

    U.S. Pricing:

  • Initial government purchase price: $19.50 per dose
  • Later government purchases: Up to $30 per dose
  • Private market price (2023): $110-130 per dose

    • International Pricing Disparities:

  • Wealthy countries paid $15-30 per dose
  • Middle-income countries faced higher prices or limited access
  • Low-income countries largely excluded from early access despite COVAX commitments

    • Profit Sharing with BioNTech: Pfizer split vaccine profits equally with German partner BioNTech, meaning each company earned approximately $17-18 billion from the vaccine in 2021. BioNTech contributed core mRNA technology developed with public funding, while Pfizer provided manufacturing and distribution.

    Market Dominance and Government Dependency

    Pfizer's COVID vaccine success relied on government guarantees:

    Advance Purchase Agreements:

  • U.S. government committed to purchasing 300+ million doses before approval
  • European Union and other governments signed similar advance purchase deals
  • Agreements eliminated commercial risk and guaranteed demand

    • No-Bid Contracts:

  • Many government contracts awarded without competitive bidding
  • Terms often favorable to Pfizer including liability waivers and guaranteed payments

    • Regulatory Capture Benefits:

  • FDA Commissioner Scott Gottlieb joined Pfizer's board in 2019, two years before COVID vaccine approval
  • Former FDA officials in Pfizer leadership positions facilitated regulatory relationships
  • Revolving door between FDA and Pfizer created alignment of interests

    • Intellectual Property Monopoly

    Pfizer and BioNTech fiercely protected patent monopolies despite public health arguments for broader access:

    Patent Enforcement:

  • Refused to share mRNA technology or manufacturing know-how with developing countries
  • Opposed TRIPS waiver that would have allowed generic production
  • Used intellectual property protections to maintain market control

    • Production Bottlenecks:

  • Limited manufacturing capacity created artificial scarcity
  • Refused technology transfer to qualified manufacturers in Global South
  • Maintained pricing power through controlled supply

    • Global Inequity: By late 2021, high-income countries had vaccinated 70%+ of their populations while low-income countries remained below 5%—a disparity driven partly by Pfizer's refusal to expand production through technology sharing.

    Stock Buybacks and Shareholder Returns

    Pfizer used COVID profits to enrich shareholders rather than invest in broader public health:

    2022 Commitments:

  • Announced plans for stock buybacks using COVID profits
  • Increased dividend payments to shareholders
  • Executive compensation tied to revenue growth incentivized profit maximization

    • CEO Compensation: CEO Albert Bourla received approximately $33 million in total compensation in 2021, substantially increased from pre-pandemic levels, with bonuses tied directly to vaccine revenue and profits.

    Paxlovid: Repeating the Profit Model

    Pfizer replicated its vaccine profit strategy with Paxlovid, its COVID treatment pill:

    Development:

  • Acquired Paxlovid through purchase of compounds originally developed by academic researchers
  • Received $5.29 billion U.S. government commitment for 10 million treatment courses
  • Government eliminated commercial risk through advance purchase

    • Pricing:

  • U.S. government paid approximately $530 per course
  • Production cost estimated at $20-30 per course
  • Margin of 1,700%+ on government-funded treatment

    • Access Restrictions:

  • Maintained patent monopolies preventing generic production
  • Limited licensing to selected manufacturers
  • Restricted access in developing countries through pricing and supply controls

    • Political Influence and Lobbying

    Pfizer leveraged COVID profits to expand political influence:

    Lobbying Expenditures:

  • Spent $13+ million on federal lobbying in 2021
  • Focused on protecting patent rights and opposing price controls
  • Lobbied against government drug price negotiation provisions

    • Campaign Contributions:

  • Pfizer PAC and executives contributed heavily to members of health committees
  • Donations targeted legislators considering pharmaceutical regulation
  • Maintained bipartisan contribution strategy to ensure influence regardless of party control

    • Revolving Door:

  • Former FDA Commissioner Scott Gottlieb on Pfizer board during pandemic
  • Multiple former government officials in Pfizer leadership positions
  • Created alignment between regulatory decisions and corporate interests

    • Contrast with Public Sector Alternatives

    Other COVID vaccine development models highlighted alternatives to Pfizer's profit-maximization approach:

    AstraZeneca/Oxford:

  • Initially committed to selling vaccine at-cost during pandemic
  • Later abandoned non-profit commitment but maintained lower pricing than Pfizer
  • Demonstrated viability of public-interest pharmaceutical development

    • Moderna:

  • Received $1.5+ billion in direct U.S. government funding for vaccine development
  • Despite complete public funding, retained patent rights and charged premium prices
  • Pledged not to enforce patents during pandemic but maintained pricing power

    • Public Sector Capacity: These examples demonstrated that government could have directly funded and managed vaccine development without creating private profit monopolies, but chose instead to subsidize private companies' profit extraction.

    Long-Term Revenue Strategy

    Pfizer positioned COVID vaccines for ongoing revenue:

    Annual Boosters:

  • Projected annual or semi-annual boosters creating recurring revenue
  • Compared to flu vaccine model with perpetual market
  • Estimated potential for $10+ billion annual revenue indefinitely

    • Variant-Specific Vaccines:

  • Developed updated vaccines for new variants
  • Each update provided opportunity for new pricing and sales
  • Government dependency on Pfizer for pandemic response created negotiating leverage

    • Combination Vaccines:

  • Developed COVID-flu combination vaccines to capture additional market share
  • Strategy to make COVID vaccines routine like flu shots, ensuring ongoing profits

    • Regulatory Capture: FDA Relationships

    The FDA-Pfizer relationship during COVID revealed regulatory capture:

    Gottlieb Board Position: Scott Gottlieb served as FDA Commissioner 2017-2019, then joined Pfizer's board in 2019—just before the pandemic. During 2020-2021, Gottlieb frequently appeared on media as a Pfizer board member while discussing FDA regulatory decisions, creating conflicts of interest.

    Expedited Approvals:

  • FDA granted Emergency Use Authorization with unprecedented speed
  • Full approval (BLA) granted in August 2021 for Comirnaty despite ongoing questions
  • Regulatory accommodations exceeded those provided to competitors

    • Post-Market Surveillance:

  • FDA relied heavily on Pfizer-provided safety data
  • Limited independent safety monitoring
  • Adverse event reporting system (VAERS) understaffed and under-resourced

    • Public Health vs. Profit Maximization

    Pfizer's COVID response prioritized shareholder value over global health:

    Production Limitations:

  • Maintained artificial scarcity to protect pricing power
  • Refused to expand production through technology transfer
  • Prioritized wealthy country contracts over global access

    • Dose Hoarding:

  • Wealthy countries purchased multiple doses per capita while poor countries lacked supply
  • Pfizer sold to highest bidders rather than prioritizing epidemiological need
  • Enabled vaccine nationalism that prolonged global pandemic

    • Variant Emergence: Inadequate global vaccination due to access barriers allowed new variants to emerge, prolonging the pandemic and creating opportunities for additional variant-specific vaccine sales—perversely incentivizing continued global inequity.

    Taxpayer Subsidies, Private Gains

    The fundamental structure of Pfizer's COVID profits represented privatization of public investment:

    Public Contributions:

  • Decades of government-funded mRNA research
  • Billions in advance purchase commitments
  • Complete liability protection
  • Regulatory fast-tracking
  • Government-funded distribution infrastructure

    • Private Capture:

  • Full patent rights to publicly-funded technology
  • Monopoly pricing power
  • Stock buybacks and dividends to private shareholders
  • Executive bonuses tied to revenue from public health emergency

    • Precedent for Future Pandemics

    Pfizer's COVID vaccine profiteering established a dangerous precedent:

    Government Dependency:

  • Demonstrated government will fund research, assume risk, and provide liability protection
  • Established that companies can extract maximum profits during health emergencies
  • No mechanisms created to recover public investment or limit profits

    • Next Pandemic Blueprint:

  • Pharmaceutical companies learned they can profit enormously from public health crises
  • Government will not impose price controls or profit limitations during emergencies
  • Intellectual property monopolies will be protected even when blocking global health response

    • Regulatory Capture Reinforced:

  • FDA-Pfizer alignment during crisis strengthened revolving door relationships
  • Demonstrated regulators will prioritize industry interests even during public health emergencies
  • No reforms implemented to prevent future conflicts of interest

    • Alternative Models Rejected

    The pandemic presented opportunity to fundamentally restructure pharmaceutical development:

    Public Manufacturing:

  • Government could have directly manufactured vaccines using publicly-funded technology
  • Would have eliminated private profit extraction
  • Rejected in favor of private sector enrichment

    • Patent Pools:

  • Could have required patent sharing as condition of public funding
  • Would have enabled rapid global production scale-up
  • Rejected due to pharmaceutical industry lobbying

    • Price Controls:

  • Could have imposed reasonable pricing in exchange for liability protection and advance purchases
  • Would have limited profiteering while ensuring access
  • Rejected as politically infeasible due to industry influence

    • The Cost of Regulatory Capture

    Pfizer's $22 billion annual COVID profit demonstrates the human and financial cost of pharmaceutical industry regulatory capture:

  • Taxpayer-funded research privatized for corporate profit
  • Artificial scarcity prolonged pandemic and cost lives
  • Intellectual property monopolies blocked global access
  • Government health crisis became private enrichment opportunity
  • No mechanisms to recover public investment or ensure fair pricing

    • The pandemic exposed how thoroughly the pharmaceutical industry has captured regulatory and political systems. When faced with the greatest public health crisis in a century, government chose to subsidize record corporate profits rather than prioritize public health—a choice enabled by decades of regulatory capture, lobbying, and political corruption that subordinated public welfare to pharmaceutical industry interests.

    Pfizer's COVID vaccine profits represent not the success of market-driven innovation, but the failure of government to protect public interest when confronting industry power. The public funded the research, assumed the risk, and provided the market—then watched private companies extract tens of billions in profits while millions worldwide died waiting for access to vaccines the public had already paid to develop.